Current Edition

ADC

Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate …

Continue Reading →
multicentre study

Emotional Brain’s FSIAD Products Lybrido and Lybridos show High Efficacy and Safety in Phase 2B Trials

Emotional Brain is pleased to announce the publication of positive phase 2B results in the authoritative Journal of Sexual Medicine. Lybrido and Lybridos were successfully tested …

Continue Reading →
clinical trial

Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that TG02 has passed the initial …

Continue Reading →
clinical study

FDA lifts clinical hold on fitusiran

Sanofi Genzyme, the specialty care global business unit of Sanofi, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the …

Continue Reading →
chemotherapy

Roche announces Phase III study results for the treatment of people with advanced kidney cancer

Roche has announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq® …

Continue Reading →
clinic

New Analysis Shows High Rates of Skin Clearance as Measured by Absolute PASI in Patients With Moderate to Severe Plaque Psoriasis Treated With Janssen’s TREMFYA® (guselkumab)

Janssen-Cilag International NV (“Janssen”) presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute Psoriasis Area and Severity Index score (PASI), as …

Continue Reading →
clinical

Bioclinica Launches Clinical Adjudication Led by Experienced Medical Specialists and Researchers for Enhanced Safety & Efficacy in Clinical Trials

Bioclinica®, the world-leading provider of technology-enabled solutions for clinical research, today announces the launch of Bioclinica Clinical Adjudication, a transformational offering in which medical specialists …

Continue Reading →
approval

Summit completes initial dosing trials on Duchenne muscular dystrophy drug

Summit Therapeutics has completed the half-way stage of dosing of its Duchenne Muscular Dystrophy (DMD) candidate ezutromid in a 48-week phase 2 trial, dubbed PhaseOut …

Continue Reading →